Corteva Inc Stock Price, News & Analysis

Corteva, Inc. (NYSE: CTVA) will disclose its Q1 2023 earnings on May 3, 2023, after market close, and will host a live webcast on May 4, 2023, at 9:00 a.m. ET. The earnings call will be supported by a slide presentation available on their Investor Events page. Corteva is a global agriculture company focused on delivering solutions for agriculture challenges, emphasizing innovation and customer engagement.

Corteva Agriscience has launched Adavelt™ active, a novel fungicide, in Canada, Australia, and South Korea. This product, which is now approved for commercial sale, represents a new mode of action against crop diseases that threaten yields. Adavelt™ active will be available for lentil crops in Canada for the 2023 growing season. This innovative fungicide has preventative and curative properties, enhancing crop protection and reducing resistance risks. Corteva plans to expand Adavelt's availability in additional countries pending regulatory approvals. The launch reflects Corteva's ongoing commitment to R&D for sustainable agricultural solutions.

Bunge (NYSE: BG), Corteva (NYSE: CTVA), and Chevron (NYSE: CVX) announced a collaboration to introduce proprietary winter canola hybrids aimed at producing low-carbon plant-based oil. This initiative targets the renewable fuels market in the southern United States, creating a sustainable crop rotation for farmers while enhancing soil health. The plan includes a pilot program in the 2022-23 growing season to optimize management practices. Executives from the collaborating companies emphasized the importance of feedstock innovation for advancing a lower-carbon energy future and supporting agricultural productivity.

Corteva Agriscience has announced the commercial launch of Vorceed™ Enlist® corn products, targeting U.S. farmers in high corn rootworm pressure areas within the Corn Belt. This new technology combines three modes of above-ground and below-ground insect protection, incorporating RNAi technology and tolerance to four herbicides for better weed management. Through the exclusive Corteva Horizon Network, select farmers will gain early access to these innovations in 2023, with broader offerings expected by mid-decade. The initiative aims to enhance productivity and profitability for farmers while gathering feedback to improve future product launches.

Corteva (NYSE: CTVA) has solidified its position as a global leader in the Biologicals market by acquiring Symborg, a microbiological technology firm in Spain, and Stoller, an independent Biologicals company in Texas. These acquisitions, announced in late 2022, aim to enhance sustainable farming solutions and are expected to positively impact EBITDA in 2023. Corteva's CEO, Chuck Magro, highlighted the strategic advantage of combining the expertise of both companies with Corteva's innovation capabilities. The biologicals market is projected to grow significantly, making these acquisitions vital to Corteva's growth strategy.

Corteva, Inc. (NYSE: CTVA) announces that CEO Chuck Magro will present at the Bank of America Securities 2023 Global Agriculture & Materials Conference on March 1, 2023, at 8:50 a.m. ET. The presentation will be available via live webcast through the Corteva Investor Relations website. A replay will be provided 24 hours post-event, accessible until June 2, 2023. Corteva is a leading global agriculture company focused on innovative solutions for agriculture challenges, with a diverse range of seed, crop protection, and digital products. More details can be found on the Corteva website.

Corteva (NYSE: CTVA) announced the commercial launch of Optimum GLY canola, an advanced herbicide-tolerant trait technology, for the 2023 planting season in Canada and the United States. This product will be available through Pioneer and Brevant seed brands. Optimum GLY is designed to enhance weed control and provide flexibility in herbicide applications, improving crop management for farmers. The technology aims to address farm-level challenges while supporting global food security. Demonstration trials will be held in Australia in preparation for a full launch in 2024.

Corteva, Inc. (NYSE: CTVA) reported its fourth quarter and full-year 2022 results, highlighting net sales of $3.83 billion for Q4, a 10% increase year-over-year. However, the company faced a loss from continuing operations of $(41) million for Q4 and $1.22 billion for FY 2022, reflecting declines of 33% and 32% respectively. Full-year net sales rose 11% to $17.46 billion, with an operating EBITDA of $3.22 billion and operating EPS of $2.67. Guidance for 2023 estimates net sales between $18.1 billion and $18.4 billion, marking a 5% growth.